BCAX Bicara Therapeutics Inc.

Nasdaq www.bicara.com


$ 16.10 $ 0.65 (4.2 %)    

Thursday, 20-Nov-2025 15:54:31 EST
QQQ $ 585.63 $ -26.04 (-4.26 %)
DIA $ 458.41 $ -8.22 (-1.76 %)
SPY $ 652.85 $ -20.05 (-2.98 %)
TLT $ 89.28 $ 0.29 (0.32 %)
GLD $ 374.72 $ -0.48 (-0.13 %)
$ 15.18
$ 15.51
$ 16.04 x 22
$ 16.12 x 36
$ 15.51 - $ 17.04
$ 7.80 - $ 22.68
577,719
na
828.28M
$ 1.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-27-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price ...

Core News & Articles

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of...

 4-biotech-stocks-seeing-explosive-momentum-gains

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here...

Core News & Articles

https://www.sec.gov/Archives/edgar/data/2023658/000119312525230307/d54249ds3.htm

Core News & Articles

HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price tar...

Core News & Articles

Piper Sandler analyst Kelsey Goodwin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Overweight rating and an...

Core News & Articles

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $...

 bicara-therapeutics-shares-sink-over-43-on-mixed-phase-11b-trial-results-whats-going-on

Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data.

Core News & Articles

Wells Fargo analyst Eva Fortea Verdejo upgrades Bicara Therapeutics (NASDAQ:BCAX) from Underweight to Equal-Weight and maint...

Core News & Articles
Market-Moving News for May 23rd
05/23/2025 11:07:46

OKLO: 24% | Shares of OKLO and nuclear-linked stocks are trading higher amid report that President Trump to sign orders to boos...

Core News & Articles

Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunct...

Core News & Articles

HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price tar...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION